

Indicators of Success:
Activities and Metrics

Immediate goals (e.g. end of 2017)

Category	Indicators
<i>Use of the CCTAM</i>	<ul style="list-style-type: none"> • CCTAM pilot with IMC member companies starts
	<ul style="list-style-type: none"> • Use of the CCTAM is extended to BIOTECanada member companies
<i>Communications and Outreach</i>	<ul style="list-style-type: none"> • The CCTAM’s full website is launched
	<ul style="list-style-type: none"> • CCTAM outreach (via meetings and conference demos/presentations, poster presentation, social media) continues
	<ul style="list-style-type: none"> • Provincial and Pan-Canadian Outreach is maintained and continued with the goal of additional partnerships for data and use of the CCTAM code with the goals of data being added to the CCTAM and enabling organization to build up their CT capacity
<i>Data Collection and Database Development</i>	<ul style="list-style-type: none"> • Work started re IMC member companies’ clinical trial sites/investigator agreements including a clause re adding their data to the CCTAM
	<ul style="list-style-type: none"> • IMC member companies approach their investigators and sites asking endorsing the CCTAM (i.e. asking them to join the CCTAM)
	<ul style="list-style-type: none"> • Institutional, Clinical Research Organizations (CROs), Site Management Organizations (SMOs) and disease networks (which we currently lack with some minor exceptions) data starts being populated (5%)
	<ul style="list-style-type: none"> • Industry starts to creates assets in the CCTAM

Medium-term goals (e.g. mid to end of 2018):

Category	Indicators
<i>Use of the CCTAM</i>	<ul style="list-style-type: none"> • CCTAM pilot with IMC member companies is underway
	<ul style="list-style-type: none"> • BIOTECanada member companies start to use the CCTAM. Potential pilot with some of them?
<i>Communications and Outreach</i>	<ul style="list-style-type: none"> • CCTAM’s website continues to provide new and relevant content
	<ul style="list-style-type: none"> • CCTAM maintains and grows its online and social media presence
	<p>Provincial and Pan-Canadian Outreach is maintained and continued with the goal of additional partnerships for data and use of the CCTAM code with the goals of data being added to the CCTAM and enabling organization to build up their CT capacity</p>
<i>Data Development and Data Development</i>	<ul style="list-style-type: none"> • Potentially develop new functionality as needed
	<ul style="list-style-type: none"> • IMC member companies’ clinical trial sites/investigator agreements start to include a clause re adding their data to the CCTAM (5%)
	<ul style="list-style-type: none"> • Institutional, Clinical Research Organizations (CROs), Site Management Organizations (SMOs) and disease networks data is being populated (40%)
	<ul style="list-style-type: none"> • More site and investigators data continues to be populated (40%)
	<ul style="list-style-type: none"> • Advance the work re IMC member companies’ clinical trial sites/investigator agreements including a clause re adding their data to the CCTAM
	<ul style="list-style-type: none"> • Already populated CCTAM data assets create update their assets
	<ul style="list-style-type: none"> • Industry continues to creates assets in the CCTAM
	<ul style="list-style-type: none"> • The CCTAM functionality indicating having done CTs with assets listed in the CCTAM is being used

Long-term (e.g. after 2018):

Category	Indicators
<p><i>Use of the CCTAM</i></p>	<ul style="list-style-type: none"> • CCTAM pilot with IMC member companies produces results and input for the future of the CCTAM
	<ul style="list-style-type: none"> • The CCTAM is one of frequently used by IMC member companies resources when locating investigators and sites for clinical trials in Canada
	<ul style="list-style-type: none"> • The CCTAM discussion forum functionality is used by the CCTAM members
	<ul style="list-style-type: none"> • BIOTECanada member companies also consistently use the CCTAM
<p><i>Communications and Outreach</i></p>	<ul style="list-style-type: none"> • CCTAM has substantial online and social media presence
	<ul style="list-style-type: none"> • Provincial and Pan-Canadian Outreach is maintained and continued with the goal of additional partnerships for data and use of the CCTAM code with the goals of data being added to the CCTAM and enabling organization to build up their CT capacity
<p><i>Data Collection and Database Development</i></p>	<ul style="list-style-type: none"> • IMC member companies' clinical trial sites/investigator agreements include a clause re adding their data to the CCTAM (40%)
	<ul style="list-style-type: none"> • The CCTAM includes close to 60% of all clinical trial sites in Canada (lack of total number to compared against)
	<ul style="list-style-type: none"> • The CCTAM includes close to 80% of all institutions/hospitals/etc. that conduct CTs in Canada
	<ul style="list-style-type: none"> • The CCTAM includes close to 50% of all Clinical Research Organizations (CROs), Site Management Organizations (SMOs) and disease networks
	<ul style="list-style-type: none"> • The CCTAM includes close to 50% of all patient registries
	<ul style="list-style-type: none"> • The CCTAM includes close to 60% of all patient organizations that have CT activities
	<ul style="list-style-type: none"> • The CCTAM includes close to 50% of all investigators (lack of total number to

Category	Indicators
	compared against)
	<ul style="list-style-type: none"> • The CCTAM includes close to 80% of all industry (i.e. major companies that conduct CTs in Canada)
	<ul style="list-style-type: none"> • Already populated CCTAM data assets continue to update their assets, at least every 2 years
	<ul style="list-style-type: none"> • The CCTAM discussion forum functionality is used by the CCTAM members
	<ul style="list-style-type: none"> • Metrics implemented to measure CCTAM positive impact on clinical trials in Canada (% growth)
	<ul style="list-style-type: none"> • Further functionality development is underway as per recommendations of CCTAM members